September 23, 2019 06:00 ET | Source: Xynomic Pharmaceuticals Holdings, Inc. SHANGHAI, Sept. 23, 2019 (GLOBE NEWSWIRE) — Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, today
Details

September 13, 2019 15:58 ET | Source: Xynomic Pharmaceuticals Holdings, Inc. SHANGHAI, Sept. 13, 2019 (GLOBE NEWSWIRE) —  Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, today
Details

August 30, 2019 08:41 ET | Source: Xynomic Pharmaceuticals Holdings, Inc. RALEIGH, N.C. and SHANGHAI, Aug. 30, 2019 (GLOBE NEWSWIRE) — Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug
Details

August 30, 2019 08:41 ET | Source: Xynomic Pharmaceuticals Holdings, Inc. RALEIGH, N.C. and SHANGHAI, Aug. 30, 2019 (GLOBE NEWSWIRE) — Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug
Details

August 16, 2019 16:30 ET | Source: Xynomic Pharmaceuticals Holdings, Inc. RALEIGH, N.C. and SHANGHAI, Aug. 16, 2019 (GLOBE NEWSWIRE) — Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug
Details

August 07, 2019 16:00 ET | Source: Xynomic Pharmaceuticals Holdings, Inc. RALEIGH, N.C. and SHANGHAI, Aug. 07, 2019 (GLOBE NEWSWIRE) — Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug
Details

August 01, 2019 07:00 ET | Source: Xynomic Pharmaceuticals Holdings, Inc. RALEIGH, N.C. and SHANGHAI, Aug. 01, 2019 (GLOBE NEWSWIRE) — Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage U.S.-China oncology drug
Details

July 30, 2019 07:00 ET | Source: Xynomic Pharmaceuticals Holdings, Inc. RALEIGH, N.C. and SHANGHAI, July 30, 2019 (GLOBE NEWSWIRE) — Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug
Details

July 26, 2019 12:29 ET | Source: Xynomic Pharmaceuticals Holdings, Inc. RALEIGH, N.C. and SHANGHAI, July 26, 2019 (GLOBE NEWSWIRE) — Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage U.S.-China oncology drug
Details

RALEIGH, N.C. and SHANGHAI, June 12, 2019 (GLOBE NEWSWIRE) —  Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, Nasdaq: XYN), a clinical stage US-China oncology drug development company, announced that it recently held a pre-IND meeting with the
Details

RALEIGH, N.C. and SHANGHAI, June 06, 2019 (GLOBE NEWSWIRE) —  Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, Nasdaq: XYN), a clinical stage US-China oncology drug development company, announced that Xynomic has dosed the first patient in a
Details

RALEIGH, N.C. and SHANGHAI, May 21, 2019 (GLOBE NEWSWIRE) — Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”), a clinical stage US-China oncology drug development company (XYN), announced today that long-term follow up data of exceptional responders to
Details

Xynomic Pharmaceuticals Holdings, Inc. (Nasdaq: XYN), a clinical stage US-China oncology drug development company, and its collaborators will present at the American Society of Clinical Oncology (“ASCO”) 2019 Annual Meeting to be held in Chicago from May 31, 2019 – June
Details

On Thursday, March 28th, Bayer, ChinaBio and Shanghai Healthcare Drinks held a discussion panel entitled “BioPharma Investment and Partnering in China”. The event was hosted by Bayer at its Shanghai Pudong Office, where it brought
Details

RALEIGH, N.C. and SHANGHAI, March 20, 2019 /PRNewswire/ — Xynomic Pharmaceuticals, Inc. (“Xynomic”), a clinical stage US-China oncology drug development company, and Bison Capital Acquisition Corporation (Nasdaq: BCAC), jointly announced that Xynomic and its collaborators will present at the American Society
Details

RALEIGH, N.C. and SHANGHAI, March 16, 2019 /PRNewswire/ — Xynomic Pharma, a clinical stage US-China oncology drug development company, and Bison Capital Acquisition Corp. (Nasdaq: BCAC), today jointly announced that China, Spain and Poland authorities have approved Xynomic’s application to conduct potentially pivotal Phase 3 trial
Details

RALEIGH, N.C. and SHANGHAI, Feb. 23, 2019 /PRNewswire/ — Xynomic Pharma, a clinical stage US-China oncology drug development company, and Bison Capital Acquisition Corp. (Nasdaq: BCAC), today jointly announced the dosing of the first South
Details

  Dec 20, 2018, 10:52 ET DOVER, Del. and SHANGHAI, Dec. 20, 2018 /PRNewswire/ — Xynomic Pharmaceuticals, Inc. (“Xynomic”), a clinical stage US-China oncology drug development company, today announced that it has been granted an exclusive, worldwide license to
Details

China’s Globally Facing Future: How China’s healthcare pathfinders are leveraging the nation’s innovation, policy initiatives and access to capital markets in HK and domestic exchanges to build a globally facing industry. Five years ago, the first China
Details

Mr. Y. Mark Xu, Chairman of Xynomic Pharma, will provide an update of its innovative oncology drug pipeline at the BioCentury China Healthcare Summit 2018. Mr. Xu will present at 12:55 pm on Tuesday, November
Details

NEW YORK, NY and SHANGHAI, China, Sept. 12, 2018 (GLOBE NEWSWIRE) –– Bison Capital Acquisition Corp. (“BCAC”, NASDAQ: BCAC) and Xynomic Pharmaceuticals, Inc. (“Xynomic”), a U.S.-China clinical stage innovative oncology drug development company, today jointly
Details

The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.

CHEYENNE, Wyo., Dec. 1, 2017 /PRNewswire/ — Xynomic Pharma, a clinical stage US oncology drug development company, today announced that it will initiate a Ph 1/2 trial, in collaboration with Janssen R&D, LLC (Janssen Pharmaceutical Companies of
Details

CHEYENNE, Wyo., Oct. 30, 2017 /PRNewswire/ — Xynomic Pharma, a clinical stage US oncology drug development company, today announced that it has acquired exclusive global rights to develop, manufacture and commercialize BI 882370, a 2nd-generation RAF inhibitor,
Details

Mr. Y. Mark Xu, Chairman, CEO and President, has been invited to speak at this high profile conference. Other presenting companies include Roche, Sanofi, Hengrui and Sino Biopharm. The venue is Mandarin Oriental Hotel, Hong
Details

CHEYENNE, Wyo., May 22, 2017 /PRNewswire/ — Xynomic Pharma, a clinical stage US oncology drug R&D company, today announced that it has entered into a strategic partnership with the University of California San Francisco (“UCSF”) to conduct
Details

Sponsored by NCI and UCSF 51 patients (72% had received two or more lines of therapy in the locally advanced or metastatic setting), Phase 1b, open-label, dose-escalation/expansion trial of Abexinostat in combination with GSK’s pazopanib
Details

March. 8, 2017 — Xynomic Pharmaceuticals, Inc., a US-China oncology startup, has acquired Greater China rights to a novel ACAT-1 inhibitor for cancer indications from Resarci Therapeutics of West Lafayette, Indiana. It will be tested
Details

CHEYENNE, Wyoming, Feb. 24, 2017 /PRNewswire/ — Xynomic Pharmaceuticals, Inc., an oncology drug research and development company, today announced that it has acquired exclusive worldwide rights to develop, manufacture and commercialize Abexinostat, a potentially best-in-class
Details